<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04033107</url>
  </required_header>
  <id_info>
    <org_study_id>ZNCM</org_study_id>
    <nct_id>NCT04033107</nct_id>
  </id_info>
  <brief_title>High Dose Vitamin C Combined With Metformin in the Treatment of Malignant Tumors</brief_title>
  <official_title>Clinical Research of High Dose Vitamin C Combined With Metformin in the Treatment of Malignant Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Zhongnan Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Zhongnan Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an open, prospective, single-arm, multi-cohort clinical study to evaluate the
      efficacy and safety of high-dose vitamin C combined with metformin in the treatment of
      malignant tumors.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">July 2019</start_date>
  <completion_date type="Anticipated">December 2022</completion_date>
  <primary_completion_date type="Anticipated">June 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression-free survival</measure>
    <time_frame>up to 12 weeks</time_frame>
    <description>Defined as time from first dose of treatment to death from any cause, or even radiological detection/or clinical of disease progression.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>up to 12 weeks</time_frame>
    <description>Defined as time from first dose of treatment until death.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective response rate</measure>
    <time_frame>up to 12 weeks</time_frame>
    <description>Overall Response Rate, as determined by the percentage of patients achieving Partial or Complete response per RECIST 1.1.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease control rate</measure>
    <time_frame>up to 12 weeks</time_frame>
    <description>Disease Control Rate: the number of patients with a CR, PR or SD lasting at least 2 months per RECIST 1.1.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes of quality of life</measure>
    <time_frame>up to 12 weeks</time_frame>
    <description>Examination of quality of life by EORTC QLQ-C30 questionnaire every 8 weeks.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with treatment-related adverse events as assessed by CTCAE v3.0</measure>
    <time_frame>up to 12 weeks</time_frame>
    <description>The number of grade 1-4 and grade 5 (fatal) NCI Common Terminology Criteria for Adverse Events Version 3.0 (CTCAE) events during treatment. All patients will be evaluable for toxicity from the time of their first treatment.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Hepatocellular Cancer</condition>
  <condition>Pancreatic Cancer</condition>
  <condition>Gastric Cancer</condition>
  <condition>Colorectal Cancer</condition>
  <arm_group>
    <arm_group_label>Treatment arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Vitamin C combined with metformin</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vitamin C</intervention_name>
    <description>Participants will receive intravenous Vitamin C injection (dose: 1.5g/kg, D1-3, every 2 weeks), treatment termination when the disease progress is confirmed.</description>
    <arm_group_label>Treatment arm</arm_group_label>
    <other_name>Ascorbic acid</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metformin</intervention_name>
    <description>Participants will orally take metformin 4g daily.</description>
    <arm_group_label>Treatment arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. 18 years to 75 years.

          2. Had a disease status that was measurable or evaluable as defined by Response
             Evaluation Criteria in Solid Tumors (RECIST, version1.1)： Cohort A: patients with
             advanced hepatocellular carcinoma who had failed previous standard first-line therapy
             and could not tolerate or reject existing therapies.

             Cohort B: patients with advanced pancreatic cancer who had previously failed standard
             first-line therapy, could not tolerate or reject existing therapies.

             Cohort C: patients with advanced gastric cancer who had failed previous standard
             second-line or above treatment, who could not tolerate or reject existing therapies.

             Cohort D: patients with advanced colorectal cancer who had failed previous standard
             second-line or above treatment, who could not tolerate or reject existing therapies.

          3. Adequate hepatic, renal, heart, and hematologic functions (hemoglobin ≥80g/L,
             platelets ≥ 80×10^9/L, neutrophils ≥ 1.5×10^9/L, total bilirubin within 1.5×the upper
             limit of normal(ULN), ALT and AST≤2.5×the ULN (If liver metastases, serum
             transaminase≤5×the ULN), serum creatine ≤ 1.5 x ULN, creatinine clearance rate &gt;
             50ml/min).

          4. At least 4 weeks after the last anti-tumor treatment (surgery, chemotherapy,
             radiotherapy, biotherapy or endocrine therapy) before enrollment.

          5. Had a life expectancy of at least 3 months.

          6. Had an Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0, 1, or
             2.

          7. Signed informed consent.

        Exclusion Criteria:

          1. In the past or at the same time with other malignant tumors (already cure period of IB
             or cervical, lower levels of noninvasive basal cell or squamous cell cancer, obtain
             complete remission (CR) &gt; 10 years of breast cancer, obtain complete remission (CR) &gt;
             10 years of malignant melanoma, obtain complete remission (CR) &gt; 5 years except of
             other malignant tumors).

          2. Pregnant or lactating female patients.

          3. Those who have applied excessive dose of vitamin C or (and) metformin in recent 1
             month.

          4. Patients with glucose-6-phosphate dehydrogenase deficiency.

          5. Patients with hydronephrosis.

          6. Had a history of clinically significant or uncontrolled heart disease, including but
             not limited to: (1)Myocardial infarction. (2)Angina.(3)Congestive heart failure above
             grade 2 of the New York heart association (NYHA).(4)Ventricular arrhythmias requiring
             continuous treatment.(5)Supraventricular arrhythmias, including uncontrolled atrial
             fibrillation.

          7. The patients had mental disorders, and the researchers believed that the patients
             could not fully or fully understand the possible complications in this study.

          8. Have a history of immunodeficiency, including: HIV positive, or other acquired or
             congenital immunodeficiency diseases, or a history of organ transplantation.

          9. Those who cannot tolerate or may be allergic to the drugs used in this study.

         10. Participated in clinical trials of other drugs within the past 1 month.

         11. Other factors considered unsuitable for the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Fuxiang Zhou, M.D</last_name>
    <role>Study Chair</role>
    <affiliation>Wuhan University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Fuxiang Zhou, M.D</last_name>
    <phone>+86-027-67813155</phone>
    <email>fuxiang.zhou@whu.edu.cn</email>
  </overall_contact>
  <location>
    <facility>
      <name>Zhongnan Hopital of Wuhan University</name>
      <address>
        <city>Wuhan</city>
        <state>Hubei</state>
        <zip>430071</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Fuxiang Zhou, M.D</last_name>
      <phone>+86-027-67813155</phone>
      <email>fuxiang.zhou@whu.edu.cn</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>July 2019</verification_date>
  <study_first_submitted>July 20, 2019</study_first_submitted>
  <study_first_submitted_qc>July 24, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">July 25, 2019</study_first_posted>
  <last_update_submitted>July 24, 2019</last_update_submitted>
  <last_update_submitted_qc>July 24, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">July 25, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Zhongnan Hospital</investigator_affiliation>
    <investigator_full_name>Zhou Fuxiang</investigator_full_name>
    <investigator_title>Principal Investigator, Clinical Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ascorbic Acid</mesh_term>
    <mesh_term>Metformin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

